Document:

Exhibit 4.11

      

       

          

      
        	
                
                  Note: This Addendum and the negotiations carried out in connection therewith are not binding to the Lessor until duly signed by the Lessor’s
                    authorized signatories.

                

              

      

       

      

    

    Azrieli Center Holon

    

    

    ADDENDUM TO OFFICE LEASE AGREEMENT dated 15.3.15

    Option Exercise

    (hereinafter – the “Addendum”)

    

    

    Made and Entered into in Tel Aviv on 14 October 2020

    

    

    Among

     

    

    
      	
               

            	
              Kanit Hashalom Investments Ltd.,

              Private Company No. 511633158

              Of 1 Azrieli Center, Tel Aviv

               (hereinafter - the “Lessor”)

              

              

              And:

              

              

              Azrieli Center Holon (Enterprises and Management) Ltd.

              Private Company No. 514917178

              Of 26 Harokmim St., Holon

              (hereinafter - the “Management Company”)

            

    

    

    

    

    The First Party;

    
       

      

      
        	
                 

              	
                
                  And:

                   
                  

                     

                   
                  Compugen Ltd.

                  Private Company No. 511779639

                  Of 26 Harokmim St., Holon

                  (hereinafter: the “Lessee”)

                

              

      

      

    

    The Second Party;

     

    

    	
            Whereas

          	
            On 15.3.15 the parties have signed an unprotected lease agreement, together with its addendums and exhibits (including the Management Agreement) (the Agreement, together with its addendums
              and exhibits, hereinafter – the “Main Agreement”), in connection with the lease of the Leased Premises, in the center known as Azrieli Center Holon (hereinafter – the “Center”);

             

            

          
	
            And Whereas

          	
            Pursuant to the Main Agreement, the Lessee’s Lease Term ends on 14.3.21 (hereinafter – the “Lease Term”);

             

            

          
	
            And Whereas

          	
            Pursuant to the Main Agreement, the Lessee has the right to extend the Lease Term for an Additional Lease Term, subject to the terms of the Main Agreement;

             

            

          
	
            And Whereas

          	
            The Lessee has approached the Lessor and requested to extend the Lease Term for an Additional Lease Term;

             

            

          
	
            And Whereas

          	
            The Lessor and the Management Company have agreed to extend the Lease Term of the Leased Premises, subject to and in accordance with the terms of this Addendum, as further set forth herein:

          

    
       

        

      
        
          

      

       

        

      Therefore It Is Declared, Stipulated and Agreed Among the Parties as Follows:

    

     

    	1.	
            The preamble to this Addendum constitutes an integral part hereof.

          

     

    	2.	
            Capitalized terms used and not otherwise defined in this Addendum shall have the respective meaning ascribed to them in the Main Agreement.

          

     

    	3.	
            The parties hereby agree as follows:

          

     

    	

          	3.1.	
            The Lease Term shall be extended such that the Lessor hereby leases to the Lessee, and the Lessee hereby leases from the Lessor, in unprotected leasing, the Leased Premises as defined in the Main Agreement, for an Additional Lease Term
              commencing as of 15.3.21 through 14.3.26 (hereinafter – the “Additional Lease Term”).

          

     

    	

          	3.2.	
            Further to and in accordance with Section 3.1 above, the Management Agreement with the Management Company is hereby extended for an additional term until the expiration of the Additional Lease Term. The Lessee confirms and declares that it
              is aware that the Management Fees payments made by it in accordance with the Main Agreement were merely down payments based on estimates, and that it undertakes to pay any differences, as may be, with respect to the Lease Term, between what
              the Lessor owes, based on the Management Company’s financial reports, and the amounts actually paid by the Lessor, all in accordance with the terms of the Main Agreement.

          

     

    	

          	3.3.	
            The extension of the Lease Term in accordance with this Addendum constitutes an exercise of the Lessee’s right to extend the Lease Term for the First Additional Lease Term. Insofar as the Lessee has further rights to extend the Lease Term
              for Additional Lease Terms beyond the Additional Lease Term set forth in this Addendum, such rights shall remain in full force and effect, subject to and in accordance with the terms and conditions of the Main Agreement.

          

     

    	

          	3.4.	
            The Lessee currently holds an area of 245 square meters (gross), that is part of the Leased Premises in building D 12 floor, and that is currently sub-leased by the Lessee to Shviro Land Ltd. (hereinafter – the “Subleased Premises”), as well as an area of 215 square meters (gross), that is part of the Leased Premises in building D 12 floor, which the Lessor currently has no use of (hereinafter – the “Vacant

                Area”). Notwithstanding the provisions of Sections 3.1 and 3.2 above, the parties hereby agree that:

          

     

    	

          	3.4.1.	
            Upon expiration of the Lease Term, the Vacant Area shall be returned to the Lessor, and the Lessor will engage directly with Shviro Land Ltd., and commencing as of the beginning of the Additional Lease Term, the Vacant Area and the
              Subleased Premises shall no longer be considered part of the Leased Premises for purposes of the Main Agreement and this Addendum. It is hereby clarified that commencing as of the Additional Lease Term, the Lessee will no longer be liable for
              any payment with respect to the Vacant Area, including Rent and Management Fees. Commencing as of the beginning of the Additional Lease Term, the Area of the Offices and the Laboratories shall be 2,740 square meters (gross).

          

     

    
      
        

    

     

    

    	

          	3.4.2.	
            In addition, notwithstanding the Main Agreement, commencing as of the beginning of the Additional Lease Term:

             

            

            
              “Number Parking Places” 55 (fifty-five) – whilst 10 of these parking places will be reserved parking places and the remainder
                (45) will be ‘floating’ parking places.  All other terms of the Main Agreement with respect to the Number Parking Places shall remain unchanged, and it is specifically agreed that a ratio of 120% will be maintained between the number of
                license plate (numbers) transmitted to the Lessor and the Number Parking Places.

            

          

     

    	

          	3.4.3.	
             Commencing as of the beginning of the Additional Lease Term: (a) the Rent for the Area of the Offices and the Laboratories, as defined in Exhibit A of the Main Agreement, shall be in the amount of NIS 51 per square meter of the Area of
              the Offices and the Laboratories, per month, plus linkage differences and VAT as required by law, and a total of NIS 138,465 per month, plus linkage differences and VAT as required by law; and (b) the Rent for the Store-Room Area shall remain
              unchanged.

          

     

    	

          	3.5.	
            Without derogating from the terms of the Main Agreement with respect to the Second Exemption Period, commencing as of October 15, 2020 and through December 15, 2020, the Lessee shall be exempt of any Rent payments, including Rent for the
              Store-Room and Parking Fees.

          

     

    	4.	
            For the avoidance of doubt, it is hereby clarified that notwithstanding the provisions of Section 7.5 in Exhibit A of Main Agreement, during the First Additional Lease Term (as defined in the Main Agreement), a raise of 1.5% shall not
              apply to the Rent and Parking Fees rates that apply prior to the commencement of the First Additional Lease Term.

          

     

    	5.	
            The Lessee hereby undertakes that until the commencement of the Additional Lease Term, the guarantees provided to the Lessor and the insurance policies will be extended and updated, all as set forth in the Main Agreement.

          

     

    	6.	
            It is hereby clarified that the Lessor’s signature on this Addendum does not constitute agreement and/or confirmation that the Lessee has met all of its duties and obligations pursuant to the Main Agreement, and the Lessor’s signature
              Addendum does not constitute a waiver of any right and/or claim by the Lessor against the Lessee under the Main Agreement and/or pursuant to applicable law, insofar as such right and/or claim exists.

          

     

    	7.	
            All other terms and conditions of the Main Agreement, unless expressly revised and/or changed in this Addendum, shall remain unchanged and in full force and effect.

          

     

    In Witness Whereof the Parties Have Set Their Hand:

     

    	
            /s/ Kanit Hashalom Investments Ltd.

          	 	
            /s/ Azrieli Center Holon (Enterprises and Management) Ltd. P.C. No. 514917178

          	 	
            /s/ Compugen Ltd.

          
	
            The Lessor

          	 	
            The Management Company

          	 	
            The LesseeExhibit 4.14

    

     

    

    
      
        Execution Version

      

      AMENDMENT NO. 2 TO THE LICENSE AGREEMENT

       

      THIS AMENDMENT NO. 2 TO THE LICENSE AGREEMENT (this “Amendment”) is made and entered into as of September 16, 2020 (the “Amendment
          Effective Date”), by and between MedImmune Limited, a company incorporated in England and a member of the AstraZeneca Group having an address of Milstein Building, Granta Park, Abington, Cambridge, CB21 6GH (“MedImmune”) and Compugen Ltd., a an Israeli company, having an address of Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”). MedImmune and Compugen are each referred to in this Amendment as a “Party” and collectively, as the “Parties”.

       

      RECITALS

       

      	A.	
              WHEREAS, MedImmune and Compugen are parties to a License Agreement effective as of March 30, 2018, as amended on May 9, 2018 (collectively, the “Agreement”).

            

      

      

      	B.	
              WHEREAS, the Parties have agreed to clarify MedImmune’s negative covenant with respect to use of Licensed Technology.

            

       

      	C.	
              WHEREAS, in accordance with Section 18.2 of the Agreement, the Parties hereto desire to amend and modify the Agreement in accordance with the terms and subject to the
                conditions set forth in this Amendment.

            

       

      NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL COVENANTS, CONDITIONS AND AGREEMENTS HEREIN CONTAINED, THE PARTIES
        HEREBY AGREE AS FOLLOWS:

       

      	1.	
              Section 2.4 of the Agreement is hereby amended and restated in its entirety to read as follows:

            

       

      2.4          No Implied Licenses; Negative Covenant.

       

      (a)          Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, Trademarks, or other
          intellectual property Controlled by the other Party. MedImmune shall not, and shall not permit its Affiliates or Sublicensees to, practice the Licensed Technology outside the scope of the licenses granted to it under this Agreement.

       

      (b)          MedImmune agrees that neither it nor any of its Affiliates shall use or exploit in any way the Licensed Technology in order to conduct any research or development with respect to, or commercialize, any Retained
          Product, and shall require any Sublicensee to agree to not use or exploit in any way the Licensed Technology in order to research or develop or commercialize any Retained Product.

       

      	2.	
              Except as expressly set forth herein, all of the terms and conditions of the Agreement remain unchanged and are in full force and effect. Capitalized terms not
                otherwise defined in this Amendment shall have the meanings respectively ascribed to them in the Agreement.

            

       

      	3.	
              This Amendment and the Agreement constitute the complete and final and exclusive understanding and agreement of the Parties with respect to the subject matter of the
                Agreement, and supersede any and all prior or contemporaneous negotiations, correspondence, understanding and agreements, whether oral or written, between the Parties respecting the subject matter of the Agreement.

            

       

      	4.	
              This Amendment may be executed in counterparts, each of which will be deemed an original and both of which will together be deemed to constitute one agreement.  The
                Parties agree that the execution of this Amendment by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures.

            

       

      [Signature page to follow]

      
        

        

        
          
            

        

      

      IN WITNESS WHEREOF, the Parties
        hereto have caused this Amendment to be duly executed by their respective authorized representatives as of the Amendment Effective Date set forth above.

       

      	 	
              MEDIMMUNE LIMITED

               

              By: /s/ Adam McArthur

               

              Name: Adam McArthur

               

              Title: Assistant General Counsel, Corporate UK

            
	 	
               

              COMPUGEN LTD.

               

              By: /s/ Anat Cohen-Dayag

               

              Name: Anat Cohen-Dayag

               

              Title: President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]